Alprazolam inhalation - Engage Therapeutics

Drug Profile

Alprazolam inhalation - Engage Therapeutics

Alternative Names: AZ-002; Staccato® alprazolam

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexza Pharmaceuticals
  • Class Anxiolytics; Benzodiazepines; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Epilepsy
  • Discontinued Panic disorder

Most Recent Events

  • 27 Sep 2017 Alprazolam inhalation licensed to Engage Therapeutics worldwide before September 2017
  • 27 Sep 2017 Engage Therapeutics plans a phase IIa trial for epilepsy in USA
  • 07 Feb 2017 Phase-II development for Epilepsy is ongoing in USA (Inhalation, aerosol)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top